Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KDDF, J&J Launch Joint Korea Diabetes R&D Program

This article was originally published in PharmAsia News

Executive Summary

South Korea is continuing to step up open innovation initiatives with the multinational pharma sector, with the aim of accelerating global licensing out deals by domestic companies. In its latest efforts, the state-run Korea Drug Development Fund (KDDF) has tied up with J&J Innovation to develop and commercialize novel Korea-originated diabetes drugs for the global market.

You may also be interested in...



D&D Pharmatech Confident As It Takes On Parkinson’s, Alzheimer’s

After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.

Asia Deal Watch: LianBio Partners With Pfizer In Greater China, Gets Financial Backing

Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.

Rising COVID-19 Disruption Of Korea's Global R&D

As the prolonged COVID-19 pandemic continues to take a toll globally, South Korean pharma firms’ overseas drug development activities are increasingly being disrupted by the impact.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel